biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by BearDownAZon Jan 14, 2019 11:34am

110 Views

Post# 29227936

Pep Talk - Protein Science Week

A very impressive collection of speakers and research this week in San Diego at the Pep Talk - Protein Science Week conference.

https://www.chi-peptalk.com/programs

https://www.chi-peptalk.com/speaker-biographies

Good luck to Dr. Mei Mei Tian, who presents today in the Recombinant Protein Therapeutics program at 11:45 AM Pacific on "xB3 Platform Delivers a Protein-Based Interleukin 1 Receptor Antagonist across the BBB and Ameliorates Neuropathic Pain in a Preclinical Model"

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload